1. BIOTHRAX™ Anthrax Vaccine Adsorbed (AVA)

  2. Recombinant Protective Antigen (rPA) Vaccine

  3. ACAM2000™ Smallpox Vaccine

  4. IMVAMUNE™ Modified Vaccinia Ankara (MVA) Smallpox Vaccine

  5. Medical Countermeasures for Hematopoietic Acute Radiation Syn-drome (hARS)

  6. Medical Countermeasures for Viral Hemorrhagic Fevers (VHF)

  7. Broad Spectrum Antibiotics for Bacterial Threats

This executive summary compiles the key elements of each program across the spectrum of medical countermeasure activities. The key risk factors that impacted each program are summarized. Overarching conclusions from the case studies are drawn, and potential areas for future solutions are outlined.

CASE STUDY SUMMARY TABLES

The following tables are intended to depict the entire value chain for medical countermeasure development, from initial threat assessment and requirements determination to response and recovery activities. These tables demonstrate the dependencies throughout the operational spectrum for each medical countermeasure analyzed. The color coding assesses the relative risk associated with each medical countermeasure for each component of the framework. While the focus of this study is the advanced development and procurement of medical countermeasure, the risks of failure do not end when a product enters into the SNS but ultimately reside on whether that medical countermeasure can be distributed and administered to those who need it when they need it.


Case Study Summary: Left Side/Preparedness Activities Preparedness Assessment Framework Mission Components



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement